Literature DB >> 16075197

[Penile cancer--aftercare with results. How much is necessary?].

R Paul1, H van Randenborgh, S Schöler, F May, R Hartung.   

Abstract

Penile cancer is a rare tumor entity but penile carcinoma is characterized by a high recurrence rate regarding local, lymphatic, and hematogenous recurrence. The critical period for tumor recurrence is in the first 5 years. Therapeutic options for tumor recurrence can be differentiated by the type of recurrence and the preceding therapy. The prognosis of local or small lymphatic recurrence-if detected early and diligently diagnosed-can be improved significantly by radical surgery. On the other hand, systemic therapy of advanced lymphatic recurrences and hematogenous metastases will influence disease progression only marginally. Based on these considerations, the follow-up of penile cancer should be risk adapted but close as suggested by our algorithm. With a reduced, but close follow-up we can offer our patients aftercare with the consequence of improved prognosis.

Entities:  

Mesh:

Year:  2005        PMID: 16075197     DOI: 10.1007/s00120-005-0882-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  18 in total

Review 1.  Local treatment of penile squamous cell carcinoma.

Authors:  Vincenzp Ficarra; Nicola Maffei; Igor Piacentini; Najati Al Rabi; Maria Angela Cerruto; Walter Artibani
Journal:  Urol Int       Date:  2002       Impact factor: 2.089

2.  Penile cancer: a case for guidelines.

Authors:  N P Munro; P J Thomas; G P Deutsch; N J Hodson
Journal:  Ann R Coll Surg Engl       Date:  2001-05       Impact factor: 1.891

3.  Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases.

Authors:  B K Kroon; S Horenblas; A P Lont; P J Tanis; M P W Gallee; O E Nieweg
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

4.  Local recurrent tumour after penis-conserving therapy. A plea for long-term follow-up.

Authors:  S Horenblas; D W Newling
Journal:  Br J Urol       Date:  1993-12

5.  Interstitial brachytherapy for penile cancer: an alternative to amputation.

Authors:  Juanita Crook; Laval Grimard; John Tsihlias; Chris Morash; Tony Panzarella
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

6.  Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study.

Authors:  G P Haas; B A Blumenstein; R G Gagliano; C A Russell; S E Rivkin; D J Culkin; M Wolf; E D Crawford
Journal:  J Urol       Date:  1999-06       Impact factor: 7.450

7.  Prognostic factors in carcinoma of the penis: multivariate analysis of 145 patients treated with amputation and lymphadenectomy.

Authors:  A Lopes; G S Hidalgo; L P Kowalski; H Torloni; B M Rossi; F P Fonseca
Journal:  J Urol       Date:  1996-11       Impact factor: 7.450

8.  Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes.

Authors:  D Theodorescu; P Russo; Z F Zhang; C Morash; W R Fair
Journal:  J Urol       Date:  1996-05       Impact factor: 7.450

9.  Squamous cell carcinoma of the penis. III. Treatment of regional lymph nodes.

Authors:  S Horenblas; H van Tinteren; J F Delemarre; L M Moonen; V Lustig; E W van Waardenburg
Journal:  J Urol       Date:  1993-03       Impact factor: 7.450

10.  EAU Guidelines on Penile Cancer.

Authors:  E Solsona; F Algaba; S Horenblas; G Pizzocaro; T Windahl
Journal:  Eur Urol       Date:  2004-07       Impact factor: 20.096

View more
  2 in total

Review 1.  [Options in palliative therapy for penile cancer].

Authors:  E Preis; G Jakse
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

2.  [Neoadjuvant, adjuvant and palliative chemotherapy of penile cancer].

Authors:  C Protzel; A K Seitz; O W Hakenberg; M Retz
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.